Eugene Sefanov

  Clinical trials face long delays and, in some cases, are even cancelled because too few subjects are enrolled. Sponsors and CROs have different recruitment strategies, from advertising through mainstream media (although this practice is not as widespread you’d think) to the use of mobile and digital applications. But, one of the most effective ways […]

  ZS Associates, a global company that offers sales and marketing solutions to a variety of industries, has released its 2015 annual report, which takes a comprehensive look at how pharmaceutical companies are marketing to physicians. 

  Earlier this year, I highlighted how Penn Medicine is leveraging IT to support their patient care and precision medicine programs. Several weeks ago, Oracle and Penn Medicine held a joint webinar in which the academic medical center discussed their overall IT landscape. 

  For several years, the FDA has been the center of scrutiny for not having an official social media policy available on its website. According to the Union of Concerned Scientists, the FDA was the only one of 17 government agencies not to have social media policy…until now. 

  Now that December is here, I thought it would be neat to look back at what our readers found most interesting last month. Below are the top five blog posts Perficient’s life sciences practice wrote in November – they’re ranked in order of popularity, with number one being the most viewed piece. 

  Last month, Perficient attended the Oracle OpenWorld conference and presented at several sessions. One of those sessions was on how clinical trial management systems (CTMS) can support risk-based monitoring (RBM) strategies at life sciences companies. 

  The California Life Sciences Association released a new report that proves the Golden State, once again, is at the top of its game when it comes to life sciences. 

  I came across this three-minute video from Quintiles, which brilliantly discusses their approach to risk-based monitoring (RBM) and gives viewers a look into a day-in-the-life of an RBM monitoring team. 

  Presidential debates. Daraprim. Martin Shkreli. Drug pricing is what everyone’s talking about. Dr. Joshua P. Cohen, a research associate professor at the Tufts Center for the Study of Drug Development, wrote an excellent article that breaks down how drug prices are determined. He also shared some key facts that support the notion of the […]

  HIT Consultant, a digital publication focused on healthcare technology, recently shared a report by Reed Smith on mergers and acquisitions (M&A) in life sciences and how personalized medicine is playing an important role in many of today’s transactions. While pharmaceutical and biotechnology companies have not abandoned the “one-size-fits all” approach to developing drugs, many […]

  I normally don’t bother reading (consciously, at least) the comments section of news articles because they’re often full of spam or disgruntled readers. But, one particular comment posted for a Wall Street Journal article caught my eye. The article was discussing the increased use of mobile apps in clinical practice. 

  Over the last decade, the life sciences industry has gone from running clinical trials on paper or, in many cases, in Excel, to leveraging comprehensive web-based systems, such as electronic data capture (EDC) and clinical trial management systems (CTMS). But, in more recent years, the widespread use of mobile technology has enabled even more […]